[go: up one dir, main page]

WO2011093418A1 - Agent favorisant la différenciation de cellules précurseurs des adipocytes - Google Patents

Agent favorisant la différenciation de cellules précurseurs des adipocytes Download PDF

Info

Publication number
WO2011093418A1
WO2011093418A1 PCT/JP2011/051686 JP2011051686W WO2011093418A1 WO 2011093418 A1 WO2011093418 A1 WO 2011093418A1 JP 2011051686 W JP2011051686 W JP 2011051686W WO 2011093418 A1 WO2011093418 A1 WO 2011093418A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
acid
vitamin
agent
differentiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2011/051686
Other languages
English (en)
Japanese (ja)
Inventor
智暢 江連
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Publication of WO2011093418A1 publication Critical patent/WO2011093418A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a preadipocyte differentiation promoter, and more particularly, to a preadipocyte differentiation promoter containing a plant extract as an active ingredient.
  • adipocytes secrete various hormones and cytokines including leptin, adiponectin, TNF- ⁇ , resistin, and free fatty acid, and are the most active endocrine organs in the living body.
  • secretion is vigorous in visceral fat, and hypertrophic fat cells excessively secrete TNF- ⁇ , resistin, free fatty acid and the like, which are called insulin resistance-inducing molecules.
  • This is considered to cause insulin resistance and lead to lifestyle-related diseases such as diabetes, hypertension, hyperlipidemia, arteriosclerosis, and cancer. That is, visceral fat accumulation is closely related to lifestyle-related diseases.
  • Patent Document 1 a food containing a material that has an action to promote differentiation of preadipocytes and prevents large adipocytes has been developed.
  • Non-patent Document 1 adiponectin produced in large amounts from small fat cells enhances the production of collagen, hyaluronic acid and the like, which are skin matrix components (Non-patent Document 1), promotes differentiation of adipose precursor cells.
  • Non-patent Document 1 adiponectin produced in large amounts from small fat cells enhances the production of collagen, hyaluronic acid and the like, which are skin matrix components.
  • the promotion of differentiation into small adipocytes is involved in improving the skin condition such as wrinkles and sagging that occur with aging as described above. From this point as well, from preadipocytes to adipocytes There is a need for substances that promote differentiation. Among these, from the viewpoint of safety in recent years, it is particularly required to be a component derived from natural products such as plants.
  • the object of the present invention is to promote differentiation of preadipocytes into adipocytes by having an excellent adipose precursor cell differentiation promoting action, and adipose tissue in which enlarged adipocytes have accumulated mainly in small adipocytes
  • the object is to obtain an adipose precursor cell differentiation promoting agent that improves to tissues, suppresses excessive secretion of TNF- ⁇ , resistin, free fatty acids and the like, and improves skin conditions such as wrinkles and sagging with aging.
  • the present invention is a preadipocyte differentiation promoting agent comprising an extract of tencha (Rubus suavissimus S. Lee).
  • the preadipocyte differentiation promoter of the present invention prevents lifestyle-related diseases such as diabetes, hypertension, hyperlipidemia, arteriosclerosis, and cancer, and improves skin conditions such as wrinkles and sagging that occur with aging. Can do. Moreover, since the component derived from a natural product is used, it is safe even if used internally or externally for humans or animals.
  • the best mode of the present invention will be described below.
  • the present inventors have confirmed that an extract from Tencha (Rubus suavissimus S. Lee) has an effect of promoting differentiation of preadipocytes.
  • This plant extract has an excellent action for promoting differentiation of preadipocytes, promotes differentiation of preadipocytes into adipocytes, and adipose tissue in which enlarged adipocytes accumulate is reduced to small fat.
  • the plant extract of the present invention can be usefully used as a preadipocyte differentiation promoter, and can be applied to all forms of preparations (pharmaceuticals, quasi drugs, cosmetics, foods).
  • the tencha used in the present invention is a plant belonging to the genus Rosaiaceae, and is known by the name of a herbal medicine named Tenshi Kenko. Native to Asia, it is a deciduous shrub with a height of 2-3 meters. Tencha is known to have an anti-inflammatory action and an inhibitory action on saccharide-degrading digestive enzymes (see JP-A-6-192114 and JP-A-9-176019). There has never been a report that it has an action, and it has been found for the first time by the present inventors.
  • the tencha extract used in the present invention refers to various parts of each plant (flowers, flower spikes, fruit skin, fruits, stems, leaves, branches, branches and leaves, stems, bark, rhizomes, root barks, roots, seeds). Or whole grass etc.) or extracted after pulverization, or extracted as is or after pulverization with a solvent.
  • the extraction solvent include water, alcohols (for example, lower alcohols such as methanol, absolute ethanol, and ethanol, or polyhydric alcohols such as propylene glycol and 1,3-butylene glycol), ketones such as acetone, diethyl ether, and dioxane.
  • Esters such as acetonitrile and ethyl acetate, organic solvents such as xylene, benzene and chloroform can be used alone or in combination of two or more kinds, and each solvent extract is combined. Can be used even in There are no particular limitations on the extraction method, but it is usually sufficient if it is in the range of the boiling point of the solvent at room temperature and normal pressure. After extraction, it is filtered or ion exchange resin is used for adsorption, decolorization, and purification to form a solution. , Paste, gel, and powder. In many cases, it can be used as it is, but if necessary, further purification treatment such as deodorization and decoloration may be added as long as the effect is not affected.
  • the tencha extract is obtained by extracting from the tencha by the method as described above, but a commercially available product can also be used. Examples of commercially available products include Tencha extract BG (1,3-butylene glycol solution containing 1% of Tencha extract, manufactured by Maruzen Pharmaceutical Co., Ltd.).
  • the tencha extract may be prepared by arbitrarily drying, concentrating or diluting depending on the dosage form and form of the adipose precursor cell differentiation promoter to be applied and the cosmetic composition or food and drink.
  • the preadipocyte differentiation promoting agent of the present invention is characterized in that it contains an extract of tencha (Rubus suavissimus S. Lee), but can contain other various components as long as the effects of the present invention are not impaired. .
  • the extract of tencha (Rubus suavissimus S. Lee) of the present invention can be used as it is as a preadipocyte differentiation promoter, and can further be contained in a cosmetic composition or food and drink.
  • the content at that time is not particularly stipulated, and varies slightly depending on the type, quality, and expected level of action of a preadipocyte differentiation promoter, cosmetic composition or food / beverage product.
  • the solid content is 0.001% by mass or more, preferably 0.1 to 50.0% by mass.
  • the prescription may be considered so that it is poured into 200 to 300 L of bath water to obtain a similar concentration.
  • the preadipocyte differentiation promoting agent of the present invention can be used as a cosmetic to improve wrinkles, sagging and the like by blending with a base for external use.
  • the blending amount of the tencha extract is 0.001 to 5% by mass as a 1% (mass ratio) extract content in the total external preparation, Preferably it is 0.01-2 mass%, More preferably, it is 0.1-1 mass%.
  • the preadipocyte differentiation promoter of the present invention and the cosmetic composition or food or drink containing the preadipocyte differentiation promoter of the present invention are within the range that does not impair the effects of the present invention, if necessary, in addition to the essential components.
  • the components and additives exemplified below can be arbitrarily selected and used in combination.
  • vitamin A group retinol, retinal (vitamin A1), dehydroretinal (vitamin A2), carotene, lycopene (provitamin A), vitamin B group: thiamine hydrochloride, thiamine sulfate (vitamin B1) ), Riboflavin (vitamin B2), pyridoxine (vitamin B6), cyanocobalamin (vitamin B12), folic acid, nicotinic acids, pantothenic acids, biotins, choline, inositols, vitamin C group: vitamin C acid or its derivatives, vitamin D Group: Ergocalciferol (vitamin D2), cholecalciferol (vitamin D3), dihydrotaxosterol, vitamin E group: vitamin E or its derivatives, ubiquinones, vitamin K group: phytonadione (vitamin K1), menaquinone (vitamin 2), menadione (vitamin K3), mena
  • Microbial culture metabolites Yeast metabolites, yeast extract, natto metabolites, natto extract, rice fermented extract, rice bran (red rice cake, white birch) fermented extract, euglena extract, raw milk or skim milk lactic acid fermentation Products, trehalose or derivatives thereof.
  • Microbial culture metabolites Yeast metabolites, yeast extract, natto metabolites, natto extract, rice fermented extract, rice bran (red rice cake, white birch) fermented extract, euglena extract, raw milk or skim milk lactic acid fermentation Products, trehalose or derivatives thereof.
  • (6) ⁇ -hydroxy acids Glycolic acid, citric acid, malic acid, tartaric acid, lactic acid and the like.
  • Whitening agent p-aminobenzoic acid derivative, salicylic acid derivative, anthranilic acid derivative, coumarin derivative, amino acid compound, benzotriazole derivative, tetrazole derivative, imidazoline derivative, pyrimidine derivative, dioxane derivative, camphor derivative, furan derivative, pyrone Derivatives, nucleic acid derivatives, allantoin derivatives, nicotinic acid derivatives, vitamin C or derivatives thereof (vitamin C phosphate magnesium salt, vitamin C glucoside, etc.), vitamin E or derivatives thereof, kojic acid or derivatives thereof, oxybenzone, benzophenone, arbutin, Guaiazulene, shikonin, baicalin, baicalein, berberine, placental extract, ellagic acid, lucinol, etc.
  • Tyrosinase activity inhibitor Vitamin C or a derivative thereof (vitamin C phosphate magnesium salt, vitamin C glucoside, etc.), hydroquinone or a derivative thereof (hydroquinone benzyl ether, etc.), kojic acid or a derivative thereof, vitamin E or a derivative thereof, N-acetyltyrosine or a derivative thereof, glutathione, hydrogen peroxide, zinc peroxide, ellagic acid, arbutin, lucinol, silk extract, plant extract (chamomile, mulberry, toki, garlic, clam, mugwort, honeysuckle, yellowfin, dokudami, Matsuhodo, pearl barley, nettle, hops, hawthorn, eucalyptus, yarrow,retea, keihi, mankaishi, hamamelis, yamagwa, life-grass, bellflower, toshishi, goblin, shooting, mao, senkyu, do
  • Astringents Succinic acid, allantoin, zinc chloride, zinc sulfate, zinc oxide, calamine, zinc p-phenolsulfonate, potassium aluminum sulfate, resorcin, ferric chloride, tannic acid (including catechin compounds) and the like.
  • Active oxygen scavenger SOD Active oxygen scavenger SOD, catalase, glutathione peroxidase and the like.
  • Anti-inflammatory agent Itamol, indomethacin, kaolin, salicylic acid, sodium salicylate, methyl salicylate, acetylsalicylic acid, diphenhydramine hydrochloride, d-camphor, d1-camphor, hydrocortisone, guaiazulene, camazulene, chlorpheniramine maleate, glycyrrhizic acid or the like Salt, glycyrrhetinic acid or a salt thereof, licorice extract, sicon extract, age extract, propolis, etc.
  • Antibacterial / bactericidal / disinfectant Acrinol, sulfur, calcium gluconate, chlorhexidine gluconate, sulfamine, mercurochrome, lactoferrin or hydrolyzate thereof, alkyldiaminoethylglycine chloride solution, triclosan, sodium hypochlorite, chloramine T, Sarashi powder, iodine compound, iodoform, sorbic acid or its salt, salicylic acid, dehydroacetic acid, parahydroxybenzoic acid esters, undecylenic acid, thiamine lauryl sulfate, thiamine lauryl nitrate, phenol, cresol, p-chlorophenol, p-chloro -M-xylenol, p-chloro-m-cresol, thymol, phenethyl alcohol, o-phenylphenol, irgasan CH3565, halocarban, he
  • photosensitizer No. 401 N- long chain acyl basic amino acid derivative and its acid shark salts, zinc oxide, hinokitiol, Sophora root, propolis, and the like.
  • Elastase activity inhibitor Fluorophosphate diisopropyl, plant extract (Ogon, Hypericum, Clara, Mulberry leaf, Keihi, Genso pepper, Comfrey, Salvia, Elderberry, Bodaige, Buttonpi), seaweed extract and the like.
  • Stimulants Pepper tincture, nonyl acid vanillamide, cantalis tincture, ginger tincture, peppermint oil, 1-menthol, camphor, benzyl nicotinate and the like.
  • Metabolic activator Photosensitive element 301 hinokitiol, pantothenic acid or derivatives thereof, allantoin, biotin, pentadecanoic acid glyceride and the like.
  • Antiseborrheic agent Pyridoxine or a derivative thereof, sulfur, vitamin B6 and the like.
  • Muscle activator Waremoko extract (extract), powder
  • azuki powder coenzyme Q10, vitamins, amino acids and the like.
  • Metabolic activator (slimming agent) Carnitine, lipoic acid, isoflavone, caffeine, bitumen (extract (extract), powder), azuki bean powder, capsaicin, chili, ginger, vitamins, amino acids, etc.
  • the agent for promoting differentiation of preadipocytes according to the present invention and the dosage form of a cosmetic composition or food or drink containing the same are arbitrary, and capsules, powders, granules, solids, liquids, gels, bubbles, emulsions, creams, ointments It can be used in the form of a sheet or the like.
  • external pharmaceutical preparations lotions, emulsions, creams, ointments, lotions, oils, packs, and other basic cosmetics, facial cleansers and skin cleansing agents, hair removal agents, hair removal agents, after-shave lotions, pre-shave lotions , Shaving cream, foundation, lipstick, blusher, eye shadow, eyeliner, mascara, makeup cosmetics, perfumes, nail polish, nail enamel, nail enamel remover, shampoo, rinse, hair treatment, pre-hair Hair treatments for hair treatments, hair preparations, permanents, hair dyes, hair growth and hair nourishing agents, bath preparations, deodorants, deodorants, poultices, plasters, tapes, sheets, patches, aerosols
  • products such as toothpaste, fresheners, mouth rinses, sanitary cotton, wet tissue, etc.
  • the present invention will be described in more detail with reference to the following examples, but the present invention is not limited thereto. Unless otherwise specified, the amount is shown in mass%. Initially, the preparation method of the plant extract used in the present Example, the test method regarding the effect of promoting differentiation of preadipocytes, and the results will be described. 1. Preparation of sample In this example, Tencha extract BG (manufactured by Maruzen Pharmaceutical Co., Ltd.) was used as the tencha extract, but it is not limited thereto. 2. Adipose precursor cell differentiation promoting effect test method and its results The above-mentioned tencha extract was used as a test sample, and the adipose precursor cell differentiation promoting effect was measured and evaluated by the following method.
  • Tencha extract BG manufactured by Maruzen Pharmaceutical Co., Ltd.
  • Mouse 3T3-L1 cells were used as preadipocytes.
  • the cells were seeded in a 24-well plate (Asahi Techno Glass Co., Ltd.) so that the number of cells per well was 1.5 ⁇ 10 4 and cultured in DMEM medium containing 10% CS until confluent.
  • each group was divided into 4 groups of 3 wells.
  • the first group was added with tencha extract (0.25% of 1,3-butylene glycol as a solvent), second The group has a final concentration of 0.1% by weight of the tencha extract, the third group has a final concentration of 0.3% by weight of the tencha extract, and the fourth group has a final concentration of 0.5% by weight of the tencha extract.
  • DMEM containing 10% FBS contains insulin, dexamethasone and isobutylmethylxanthine (IBMX) at final concentrations of 1 ⁇ g / mL, 0.3 and 150 ⁇ mol, respectively. And added to each well, followed by static culture at 37 ° C. for 2 days. Thereafter, the medium was replaced with 10% FBS-containing DMEM medium containing 1 ⁇ g / mL insulin, and one day later, triglyceride in cells differentiated into adipocytes was stained with oil red.
  • IBMX isobutylmethylxanthine
  • the culture solution was removed, washed with PBS, fixed with 10% neutral formalin solution, washed with distilled water, and then stained with 0.35% oil red solution.
  • the dyed water was washed with dye, oilred was extracted with isopropanol, and the absorbance at 540 nm was measured.
  • FIG. the formulation example of the fat precursor cell differentiation promoter by this invention of various dosage forms is demonstrated as a formulation example. Needless to say, the present invention is not limited by these formulation examples and is specified by the scope of claims.
  • Formulation Example 1 (oil-based foundation) Fine particle titanium oxide 10.0 Mica 22.4 Kaolin 10.0 Nylon powder 5.0 Red iron oxide 0.5 Yellow iron oxide 0.5 Black iron oxide 0.1 Liquid paraffin remaining dimethylpolysiloxane 10.0 Sorbitan sesquioleate 2.0 Octyl methoxycinnamate 5.0 Adipocyte differentiation promoter of the present invention: Tencha extract 0.001 (Tencha Extract BG (Maruzen Pharmaceutical Co., Ltd.)) Perfume Appropriate amount Microcrystalline wax 6.0 Carnauba Arrow 3.0 Production method: Fine particles of titanium oxide, mica, kaolin, nylon powder, red iron oxide, yellow iron oxide and black iron oxide were thoroughly mixed and ground in a blender (powder part).
  • fragrance phase Components other than the fragrance were mixed and heated and melted at 85 ° C. (oil phase). The powder was added to this oil phase with stirring. Next, a fragrance was added and thoroughly ground and dispersed, and then filled into a container and molded to obtain an oily foundation.
  • Formulation example 2 (milky lotion) Stearic acid 6.0 Sorbitan monostearate ester 2.0 Polyoxyethylene (20 mol) sorbitan monostearate 1.5 2- (2′-Hydroxy-5′-methylphenyl) benzotriazole 8.0 Propylene glycol 10.0 Adipocyte differentiation promoter of the present invention: Tencha extract 1.0 (Tencha Extract BG (Maruzen Pharmaceutical Co., Ltd.)) Antiseptic / Antioxidant Appropriate amount of perfume Appropriate amount of purified water Propylene glycol was added to purified water and heated to maintain 70 ° C. (aqueous phase). On the other hand, other components were mixed, heated and melted, and kept at 70 ° C. (oil phase).
  • aqueous phase On the other hand, other components were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase with stirring to perform preliminary emulsification. Next, the emulsified particles of the system were made fine and uniform with a homomixer, and then rapidly cooled with good stirring to obtain a cream.
  • Formulation Example 4 Compounding ingredients Compounding amount (% by mass) Polyoxyethylene (20 mol) cetyl alcohol ether 1.0 Methylphenyl polysiloxane (20cs) 2.0 Liquid paraffin 3.0 2-Hydroxy-4-methoxybenzophenone 5.0 Warmoko extract (manufactured by Koei Kogyo Co., Ltd.) 0.1 Propylene glycol 5.0 Glycerin 2.0 Ethyl alcohol 15.0 Carboxyvinyl polymer 0.3 Hydroxypropyl cellulose 0.1 2-Aminomethylpropanol 0.1 Adipocyte differentiation promoter of the present invention: Tencha extract 0.1 Preservative Appropriate amount of perfume Appropriate amount of purified water Remaining production method: Propylene glycol was added to purified water and heated to maintain 70 ° C.
  • Adipocyte differentiation promoter of the present invention Tencha extract 1.0 Warmoko extract 1.0 Citric acid 0.1 Vitamin C appropriate amount purified water remaining

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un agent, favorisant la différenciation de cellules précurseurs des adipocytes, qui favorise la différenciation de cellules précurseurs d'adipocytes des cellules adipocytes, qui améliore le tissu adipeux dans lequel des cellules adipocytes hypertrophiques se sont accumulées et qui produit du tissu qui comprend principalement de petites cellules adipocytes, qui prévient la sécrétion excessive du TNF-α, de résistine, d'acides gras libres ou autres, et qui améliore également les états cutanés tels que les rides et l'affaissement dû à l'âge. L'agent contient un extrait de Rubus suavissimus S. Lee.
PCT/JP2011/051686 2010-01-27 2011-01-21 Agent favorisant la différenciation de cellules précurseurs des adipocytes Ceased WO2011093418A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010015108A JP2011153093A (ja) 2010-01-27 2010-01-27 脂肪前駆細胞分化促進剤
JP2010-15108 2010-01-27

Publications (1)

Publication Number Publication Date
WO2011093418A1 true WO2011093418A1 (fr) 2011-08-04

Family

ID=44319399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/051686 Ceased WO2011093418A1 (fr) 2010-01-27 2011-01-21 Agent favorisant la différenciation de cellules précurseurs des adipocytes

Country Status (3)

Country Link
JP (1) JP2011153093A (fr)
TW (1) TW201129367A (fr)
WO (1) WO2011093418A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5947047B2 (ja) * 2012-02-06 2016-07-06 花王株式会社 Ｐｐａｒ活性化剤
US20210315799A1 (en) * 2018-08-23 2021-10-14 Lg Household & Health Care Ltd. Composition for Promoting Differentiation or Proliferation of Human Adipose-Derived Stem Cell
KR102298433B1 (ko) * 2019-06-24 2021-09-09 박준한 지방세포 생착 증진용 조성물
KR102414278B1 (ko) * 2019-06-24 2022-06-29 박준한 줄기세포 생착 증진용 조성물
JPWO2024181369A1 (fr) 2023-02-27 2024-09-06

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192114A (ja) * 1991-01-25 1994-07-12 Suntory Ltd 甜茶抽出物を有効成分とする医薬並びにこれを配合した食品および化粧品
JPH09124497A (ja) * 1995-02-10 1997-05-13 Suntory Ltd Ｇｏｄタイプのエラジタンニンを有効成分とするヒアルロニダーゼ阻害剤並びにこれを配合した医薬品及び化粧品
JPH09176019A (ja) * 1995-12-26 1997-07-08 Suntory Ltd 糖質分解消化酵素阻害剤並びにこれを配合した医薬品および飲食品
JPH11279069A (ja) * 1998-03-27 1999-10-12 Ichimaru Pharcos Co Ltd 活性酸素消去剤
JP2000239144A (ja) * 1999-02-22 2000-09-05 Kose Corp ランゲルハンス細胞減少抑制剤及びこれを含有する皮膚外用剤
JP2001122757A (ja) * 1999-10-22 2001-05-08 Naris Cosmetics Co Ltd 活性酸素消去剤、抗酸化剤および化粧料
JP2002241299A (ja) * 2001-02-13 2002-08-28 Ichimaru Pharcos Co Ltd メイラード反応修復剤
JP2002255837A (ja) * 2001-03-01 2002-09-11 Mikimoto Pharmaceut Co Ltd アルドースレダクターゼ阻害剤
JP2004175734A (ja) * 2002-11-28 2004-06-24 Kose Corp 皮膚障害抑制剤、皮膚障害改善剤並びにそれらを含有する皮膚外用剤
JP2006111560A (ja) * 2004-10-14 2006-04-27 Nippon Menaade Keshohin Kk セラミド合成促進剤
JP2006124350A (ja) * 2004-11-01 2006-05-18 Nippon Menaade Keshohin Kk Ｎｍｆ産生促進剤
JP2007008907A (ja) * 2005-07-04 2007-01-18 Maruzen Pharmaceut Co Ltd 血管新生抑制剤及び外用剤
JP2007314475A (ja) * 2006-05-26 2007-12-06 Kao Corp トリアシルグリセロール合成抑制剤

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192114A (ja) * 1991-01-25 1994-07-12 Suntory Ltd 甜茶抽出物を有効成分とする医薬並びにこれを配合した食品および化粧品
JPH09124497A (ja) * 1995-02-10 1997-05-13 Suntory Ltd Ｇｏｄタイプのエラジタンニンを有効成分とするヒアルロニダーゼ阻害剤並びにこれを配合した医薬品及び化粧品
JPH09176019A (ja) * 1995-12-26 1997-07-08 Suntory Ltd 糖質分解消化酵素阻害剤並びにこれを配合した医薬品および飲食品
JPH11279069A (ja) * 1998-03-27 1999-10-12 Ichimaru Pharcos Co Ltd 活性酸素消去剤
JP2000239144A (ja) * 1999-02-22 2000-09-05 Kose Corp ランゲルハンス細胞減少抑制剤及びこれを含有する皮膚外用剤
JP2001122757A (ja) * 1999-10-22 2001-05-08 Naris Cosmetics Co Ltd 活性酸素消去剤、抗酸化剤および化粧料
JP2002241299A (ja) * 2001-02-13 2002-08-28 Ichimaru Pharcos Co Ltd メイラード反応修復剤
JP2002255837A (ja) * 2001-03-01 2002-09-11 Mikimoto Pharmaceut Co Ltd アルドースレダクターゼ阻害剤
JP2004175734A (ja) * 2002-11-28 2004-06-24 Kose Corp 皮膚障害抑制剤、皮膚障害改善剤並びにそれらを含有する皮膚外用剤
JP2006111560A (ja) * 2004-10-14 2006-04-27 Nippon Menaade Keshohin Kk セラミド合成促進剤
JP2006124350A (ja) * 2004-11-01 2006-05-18 Nippon Menaade Keshohin Kk Ｎｍｆ産生促進剤
JP2007008907A (ja) * 2005-07-04 2007-01-18 Maruzen Pharmaceut Co Ltd 血管新生抑制剤及び外用剤
JP2007314475A (ja) * 2006-05-26 2007-12-06 Kao Corp トリアシルグリセロール合成抑制剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOH, G.Y. ET AL.: "Improvement of Obesity Phenotype by Chinese Sweet Leaf Tea (Rubus suavissimus) Components in High-Fat Diet- Induced Obese Rats", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 59, no. 1, 12 January 2011 (2011-01-12), pages 98 - 104 *

Also Published As

Publication number Publication date
JP2011153093A (ja) 2011-08-11
TW201129367A (en) 2011-09-01

Similar Documents

Publication Publication Date Title
JP7054242B2 (ja) 毛乳頭細胞賦活促進剤、及びｖｅｇｆ産生促進剤
JP2003183120A (ja) 活性酸素消去剤又は化粧料組成物
JP4814415B2 (ja) 化粧料組成物
JP4179971B2 (ja) 保湿性植物抽出物並びに該抽出物を含有する外用剤、化粧料、浴用剤及び洗剤
JP4101106B2 (ja) 保湿性植物抽出物並びに該抽出物を含有する外用剤、化粧料、浴用剤及び洗浄剤
JP4551053B2 (ja) 保湿性植物抽出物並びに該抽出物を含有する保湿外用剤、化粧料、浴用剤および洗剤組成物
CN107530273A (zh) 含有缬草提取物的组合物
WO2011093418A1 (fr) Agent favorisant la différenciation de cellules précurseurs des adipocytes
JP2002363088A (ja) エラスターゼ活性阻害剤又は化粧料組成物
JP4658631B2 (ja) 入浴剤組成物
JP2000256171A (ja) 化粧料組成物
JP2005089402A (ja) 外用抗掻痒剤
JP5711879B2 (ja) 線維芽細胞増殖因子−７産生促進剤、及びそれを含有する頭皮・頭髪用化粧料、並びに飲食物
JP2009249366A (ja) コラーゲン産生促進剤、及び老化防止用皮膚外用剤
JP2009234940A (ja) 植物抽出物を含有する化粧品組成物
JP5429851B2 (ja) 活性酸素消去剤、並びに該活性酸素消去剤を用いた皮膚外用剤及び化粧料
JP2006137702A (ja) 保湿性植物抽出物並びに該抽出物を含有する外用剤、化粧料、浴用剤及び洗剤
JP4222973B2 (ja) エラスターゼの活性阻害剤および化粧品
JP2008105984A (ja) コラーゲン産生促進剤、皮膚外用剤、浴用剤及び飲食物
JP2006076902A (ja) 保湿性植物抽出物並びに該抽出物を含有する外用剤、化粧料、浴用剤及び洗剤
JP5932948B2 (ja) 線維芽細胞増殖因子−７産生促進剤、及びそれを含有する頭皮・頭髪用化粧料、並びに飲食物
JP2005089403A (ja) 外用抗掻痒剤
JP2006213610A (ja) トリプシン阻害剤
JP5859180B2 (ja) ＴＮＦ−α産生抑制剤、サイクリックＡＭＰホスホジエステラーゼ阻害剤、シクロオキシゲナーゼ−２（ＣＯＸ−２）阻害剤、エラスターゼ活性阻害剤、エストロゲン様作用剤、Ｉ型コラーゲン産生促進剤、及びＩＶ型コラーゲン産生促進剤
JP2009215251A (ja) 抗炎症剤及び抗炎症用皮膚外用剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11737128

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11737128

Country of ref document: EP

Kind code of ref document: A1